according to a statement from drugmakers AstraZeneca and Daiichi Sankyo. "Endocrine therapy is typically used in the initial treatment of HR-positive metastatic breast cancer and following ...

The conference, attended by 30,000 people involved in cancer research, care, and advocacy, kicked off following news of a $4 billion deal where Daiichi Sankyo sold rights to three cancer ADCs to ...

2025 Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a ...

Ideally, whether we look at the macro or micro level, a partnership approach is needed, involving multiple stakeholders across advocacy ... of AstraZeneca and Daiichi Sankyo's Enhertu.

SALDEF urges vigilance, advises on rights, and works with advocacy groups to ensure fair processes. Hate crimes against Sikh Americans are also a growing issue. An important aspect of SALDEF’s ...

Daiichi Sankyo, an innovative global healthcare company, has established a state-of-the-art research laboratory in San Diego, California, US, dedicated to the development of robotics, automation and ...

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast cancer and metastatic cases of the disease. The online questionnaire gathered ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...

Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer.